Drug
Anti-PD1 Monoclonal Antibody clinical trials
- studies test it
- 24
- open now
- 15
- in phase 3
- 1
- first study started
- 2018
Keep track of what changes. Save the Anti-PD1 Monoclonal Antibody studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 2023 (7)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 21
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 19
Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Sun Yat-sen University (2) · Fudan University (2) · Zhejiang University (1) · City of Hope Medical Center (1) · Georgiamune Inc (1) · The First Affiliated Hospital of Soochow University (1)
Often tested with
Tested in the same studies.
Antineoplastic Agents (2) · Capecitabine (2) · Pegaspargase (2) · Adagrasib (1) · Anti-PD-L1 Monoclonal Antibody (1) · Bevacizumab (1) · Durvalumab (1) · Tremelimumab (1)
Studies
Open first, then newest update. How each study uses Anti-PD1 Monoclonal Antibody is read from its arms, and is right about nine times in ten.
Testing it · 24
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034Written as Anti-PD1 Monoclonal Antibody
- Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsRecruitingPhase 1/2Georgiamune IncNCT06425926Written as Anti-PD-1 monoclonal antibody
- Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaRecruitingPhase 2Sun Yat-sen UniversityNCT07644897Written as Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody
- The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue SarcomaRecruitingPhase 1/2Fudan UniversityNCT05774275Written as Anti-PD-1 monoclonal antibody
- Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRCRecruitingPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07365592Written as Anti-PD-1 monoclonal antibody
- Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT05182957Written as Anti-PD-1 monoclonal antibody
- Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPCRecruitingPhase 1University of Wisconsin, MadisonNCT07090148Written as Anti-PD-1 monoclonal antibody
- A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsRecruitingPhase 1/2LigaChem Biosciences, Inc.NCT05941507Written as Anti-PD-1 monoclonal antibody
- A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior ImmunotherapyRecruitingPhase 2Jinling Hospital, ChinaNCT06255223Written as Anti-PD-1 monoclonal antibody
- A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System LymphomaRecruitingPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06556199Written as Anti-PD-1 monoclonal antibody
- Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung CancerRecruitingNot applicableEnergenx Medical LTD.NCT05987345Written as Anti-PD-1 monoclonal antibody
- Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06170710Written as Anti-PD-1 monoclonal antibody
- Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingPhase 2Fudan UniversityNCT06121700Written as Anti-PD-1 monoclonal antibody
- Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARCRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05307198Written as Anti-PD-1 monoclonal antibody
- A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05556200Written as Anti-PD-1 monoclonal antibody
- A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)CompletedPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05254899Written as Anti-PD-1 monoclonal antibody
- Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic CancerCompletedPhase 2Zhejiang UniversityNCT03983057Written as Anti-PD-1 monoclonal antibody
- A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal CancerStatus unknownPhase 2Shanghai Celfuture Biotech Co., Ltd.NCT05684211Written as Anti-PD-1 monoclonal antibody
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownPhase 3First Affiliated Hospital Xi'an Jiaotong UniversityNCT05429684Written as Anti-PD-1 monoclonal antibody
- Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownPhase 2Chinese Academy of Medical SciencesNCT05149170Written as Anti-PD-1 monoclonal antibody
See all 24 studies that test Anti-PD1 Monoclonal Antibody →
Given in every arm · 9 — Anti-PD1 Monoclonal Antibody is usual care beside what is tested
- Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialRecruitingPhase 2Yuanquan YangNCT06470971Written as Anti-PD1 Monoclonal Antibody
- Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingPhase 2Shanghai Chest HospitalNCT07830355Written as Anti-PD-1 Monoclonal Antibody
- Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic CancerRecruitingPhase 1/2Changhai HospitalNCT04146298Written as Anti-PD-1 monoclonal antibody
- First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.RecruitingPhase 1/2Corbus Pharmaceuticals Inc.NCT06603844Written as Anti-PD-1 monoclonal antibody
- A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNot applicableZhejiang Cancer HospitalNCT06349044Written as Anti-PD-1 monoclonal antibody
- IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Chinese PLA General HospitalNCT05699811Written as Anti-PD-1 monoclonal antibody
- A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid TumorsActive, not recruitingPhase 1iTeos TherapeuticsNCT06547957Written as Anti-PD-1 monoclonal antibody
- Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaSuspendedPhase 2Fudan UniversityNCT06728657Written as Anti-PD-1 monoclonal antibody
- Methotrexate Combined With Immunotherapy During Radiotherapy for Solid TumorsActive, not recruitingPhase 2Yancheng First People's HospitalNCT05522582Written as Anti-PD-1 monoclonal antibody